JP2025518522A5 - - Google Patents
Info
- Publication number
- JP2025518522A5 JP2025518522A5 JP2024568256A JP2024568256A JP2025518522A5 JP 2025518522 A5 JP2025518522 A5 JP 2025518522A5 JP 2024568256 A JP2024568256 A JP 2024568256A JP 2024568256 A JP2024568256 A JP 2024568256A JP 2025518522 A5 JP2025518522 A5 JP 2025518522A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- oligonucleotide according
- sequence
- group
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22174186 | 2022-05-18 | ||
| EP22174186.1 | 2022-05-18 | ||
| PCT/EP2023/063442 WO2023222858A1 (en) | 2022-05-18 | 2023-05-18 | Improved oligonucleotides targeting rna binding protein sites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025518522A JP2025518522A (ja) | 2025-06-17 |
| JP2025518522A5 true JP2025518522A5 (enExample) | 2026-05-21 |
Family
ID=82308571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568256A Pending JP2025518522A (ja) | 2022-05-18 | 2023-05-18 | Ｒｎａ結合タンパク質部位を標的とする改善されたオリゴヌクレオチド |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250290068A2 (enExample) |
| EP (1) | EP4526445A1 (enExample) |
| JP (1) | JP2025518522A (enExample) |
| KR (1) | KR20250011958A (enExample) |
| CN (1) | CN119213124A (enExample) |
| AR (1) | AR129362A1 (enExample) |
| AU (1) | AU2023270744A1 (enExample) |
| CA (1) | CA3257367A1 (enExample) |
| CL (1) | CL2024003521A1 (enExample) |
| CO (1) | CO2024017326A2 (enExample) |
| CR (1) | CR20240492A (enExample) |
| IL (1) | IL316608A (enExample) |
| MX (1) | MX2024014159A (enExample) |
| PE (1) | PE20250394A1 (enExample) |
| TW (1) | TW202409276A (enExample) |
| WO (1) | WO2023222858A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12612630B2 (en) | 2024-03-05 | 2026-04-28 | Takeda Pharmaceutical Company Limited | Compositions and methods for splicing modulation of UNC13A |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| CA3103429A1 (en) | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| US20200147124A1 (en) * | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| EP4185696A1 (en) * | 2020-07-23 | 2023-05-31 | F. Hoffmann-La Roche AG | Oligonucleotides targeting rna binding protein sites |
| CN118434858A (zh) * | 2021-12-07 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 靶向actl6b的反义寡核苷酸 |
-
2023
- 2023-05-18 PE PE2024002546A patent/PE20250394A1/es unknown
- 2023-05-18 EP EP23723219.4A patent/EP4526445A1/en active Pending
- 2023-05-18 CR CR20240492A patent/CR20240492A/es unknown
- 2023-05-18 IL IL316608A patent/IL316608A/en unknown
- 2023-05-18 KR KR1020247041783A patent/KR20250011958A/ko active Pending
- 2023-05-18 AR ARP230101237A patent/AR129362A1/es unknown
- 2023-05-18 AU AU2023270744A patent/AU2023270744A1/en active Pending
- 2023-05-18 CA CA3257367A patent/CA3257367A1/en active Pending
- 2023-05-18 WO PCT/EP2023/063442 patent/WO2023222858A1/en not_active Ceased
- 2023-05-18 TW TW112118586A patent/TW202409276A/zh unknown
- 2023-05-18 CN CN202380040019.6A patent/CN119213124A/zh active Pending
- 2023-05-18 JP JP2024568256A patent/JP2025518522A/ja active Pending
-
2024
- 2024-11-15 US US18/948,897 patent/US20250290068A2/en active Pending
- 2024-11-15 MX MX2024014159A patent/MX2024014159A/es unknown
- 2024-11-18 CL CL2024003521A patent/CL2024003521A1/es unknown
- 2024-12-17 CO CONC2024/0017326A patent/CO2024017326A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7740719B2 (ja) | ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成 | |
| AU678769B2 (en) | Oligonucleotide alkylphosphonothioates | |
| JP4584986B2 (ja) | ２−アリールプロピル部分を含む１本鎖及び２本鎖オリゴヌクレオチド | |
| JP2026020334A (ja) | エンドソーム切断可能なリンカー | |
| Beaucage | Solid-phase synthesis of siRNA oligonucleotides | |
| CA2453301A1 (en) | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | |
| JP2021533804A5 (enExample) | ||
| KR20190044653A (ko) | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 | |
| JP7476101B2 (ja) | ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド | |
| JP2018519811A (ja) | 修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用 | |
| KR102533038B1 (ko) | 변형된 올리고뉴클레오티드 및 사용 방법 | |
| CA2339178A1 (en) | 2'-o-aminoethyloxyethyl-modified oligonucleotides | |
| JP2007514643A5 (enExample) | ||
| JP2019534009A5 (enExample) | ||
| CN105121452A (zh) | 三环核苷和由其制备的寡聚化合物 | |
| EP3728590B1 (en) | Novel thiophosphoramidites | |
| JP2025500335A5 (enExample) | ||
| CN119698475A (zh) | 血管紧张素原的高效rna靶向(arnatar) | |
| JP2025501457A5 (enExample) | ||
| US20260049309A1 (en) | Regulation of activity of rnai molecules | |
| JPH09505307A (ja) | 多キラル合成フォスホネートオリゴマー類 | |
| JP7198768B2 (ja) | ＵｎｙＬｉｎｋｅｒ迅速切断方法 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP7476102B2 (ja) | ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド | |
| JP2021513851A5 (enExample) |